Cannabinoids — CBD, THC, CBG, CBN and more

Cannabis contains over 100 cannabinoids. This hub covers the key molecules, how they interact and how to read a lab certificate correctly.

Beyond CBD and THC we cover CBG (anti-inflammatory), CBN (sedative, from oxidised THC) and CBC (entourage booster). We show which cannabinoids must appear on a Swiss certificate and how to distinguish full-spectrum extracts from isolates.

Definition and context

Cannabinoids are the active compounds naturally occurring in cannabis. Over 100 have been identified, with THC, CBD, CBG, CBN, CBC, and their acidic precursors THCA and CBDA being the most practically relevant. These precursors only convert into their active form when heated.

The situation in Switzerland

Under Swiss law, the only metric that matters is the total THC content—meaning the sum of free THC and the converted potential of THCA. This is why reputable lab reports present both values separately alongside the total THC level. Other cannabinoids, such as CBG or CBN, are not specifically regulated as long as the legal THC limit is met.

What this means in practice

A complete Certificate of Analysis (CoA) shows the cannabinoid profile in percent, the testing laboratory, the analysis date, and the batch number. If any of these are missing, it is impossible to verify either quality or legality. Full-spectrum products contain the plant's complete profile, including terpenes, while isolates contain only the single active ingredient.

Frequently asked questions

What is the difference between THCA and THC?

THCA is the acidic, non-psychoactive precursor. Active THC is only created through heating (decarboxylation)—which is why the total THC value always accounts for the THCA content.

What are the effects of CBG?

CBG is considered a precursor cannabinoid and is currently undergoing research. There are as yet no robust, evidence-based claims regarding its effects on consumers; consequently, marketing claims are not permitted.

What is the entourage effect?

The hypothesis that cannabinoids and terpenes interact to produce a different effect when taken together compared to in isolation. While plausible, this has not yet been conclusively proven by science.

Background and development

The Swiss landscape transformed in 2011 when the federal government raised the legal limit for industrial hemp and low-THC cannabis to 1% total THC under the Narcotics Act (BetmG). This progressive shift birthed a highly regulated domestic CBD market overseen by the Federal Office of Public Health (FOPH/BAG) and Swissmedic. Since then, the scientific and regulatory framework has evolved rapidly. On 1 August 2022, Switzerland removed the previous ban on medical cannabis, allowing doctors to prescribe high-THC medical treatments directly without requiring an exceptional permit from the FOPH. Simultaneously, the country embarked on pioneering scientific pilots across major urban hubs, including Zurich, Basel, Bern, Lausanne, and Geneva. These FOPH-approved pilot studies legally distribute regulated high-THC cannabis to registered participants within a controlled, academic framework. This dual approach of commercial low-THC products and strictly monitored scientific trials defines the unique Swiss reality today.

Distinctions and misconceptions

Consumers frequently confuse natural phytocannabinoids with synthetic alternatives like HHC or spice variants, which are strictly banned under Swiss law due to unpredictable safety profiles. Another common misunderstanding is equating hemp seed oil with CBD oil. While hemp seed oil is a nutritious culinary ingredient derived from pressed seeds, it contains virtually zero cannabinoids. It is also a critical misconception that consuming legal CBD leaves you safe to drive. Swiss road traffic laws enforce a strict zero-tolerance threshold of 1.5 micrograms of THC per litre of blood. Since legal Swiss CBD products contain up to 1% THC, regular consumption can easily push you over this legal driving limit. Finally, while carrying up to 10 grams of high-THC cannabis is decriminalized and incurs only a CHF 100 fixed penalty instead of criminal prosecution, public consumption remains illegal and subject to fines across all cantons.

Decision guide for Switzerland

When selecting cannabinoid products in Switzerland, adults must prioritize transparency and compliance. Always request a Swiss-certified laboratory analysis report to verify that the total THC remains strictly under the 1% threshold, ensuring the product is fully legal to possess. Look closely at the extraction method, choosing full-spectrum products if you want the complete plant profile, or pure isolates if you must avoid trace THC entirely. Avoid products that make therapeutic, healing, or medical promises, as Swissmedic strictly prohibits health claims on non-medical products. Furthermore, reject any packaging lacking clear batch numbers, manufacturing dates, or Swiss contact details. When purchasing, expect Swiss-produced quality CBD flower to generally align with standard market rates, but avoid suspiciously cheap imports that may contain heavy metals or residual solvents. Joining a reputable Swiss cannabis club ensures access to fully verified, lab-tested products that adhere to strict federal consumer safety standards.

How does the 1.5 micrograms per litre blood limit affect CBD users in Switzerland?

Swiss road safety laws mandate a strict threshold of 1.5 micrograms of THC per litre of blood. Because Swiss legal CBD products can contain up to 1% total THC, regular or heavy consumption can lead to accumulation in the body. Consequently, you can test positive during a roadside police check even if you only consume legal CBD and do not feel impaired.

Are minor cannabinoids like CBN and CBG legal to buy and consume in Switzerland?

Yes, minor cannabinoids such as CBG, CBN, and CBC are fully legal in Switzerland. The Swiss Federal Act on Narcotics specifically regulates and limits THC content, not these non-intoxicating molecules. As long as the finished product remains under the 1% total THC threshold and does not contain any synthesised or banned compounds, these cannabinoid formulations can be legally sold and consumed.

Explore this topic further

These guides explain the background and address practical questions in the Swiss context.

Key figures

  • 220’000+ — Swiss adults regularly consume cannabis (BAG · Suchtmonitoring 2024)
  • 36% — of 15–34 year-olds have tried cannabis (EMCDDA · Country Report Switzerland 2024)
  • CHF 582M — estimated Swiss cannabis black-market revenue per year (Uni Genf · Cannabis Market Estimate 2023)
  • 7 — cities with active or approved pilot projects (BAG · Cannabis Pilotversuche 2026)

Current research

  • Cannabis use in Switzerland — Addiction Monitoring 2024 — Sucht Schweiz, BAG · 2024
  • European Drug Report — Cannabis Chapter — EMCDDA, EUDA · 2024
  • WHO Expert Committee on Drug Dependence — Cannabis Review — WHO ECDD, WHO · 2023